Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395608 | 0.89 | HTR4 (0.72) | HTR4KCNH2HTR2A | |
| SCHEMBL9055122 | 0.88 | HTR4 (0.73) | HTR4KCNH2HTR2A | |
| Oxalic Acid SCHEMBL7392734 | 0.86 | HTR4 (0.77) | HTR4KCNH2HTR2A | |
| Oxalic Acid SCHEMBL7394778 | 0.86 | HTR4 (0.77) | HTR4KCNH2HTR2A | |
| SCHEMBL7561756 | 0.86 | HTR4 (0.76) | HTR4KCNH2HTR2A | |
| Oxalic Acid SCHEMBL7393972 | 0.86 | HTR4 (0.75) | HTR4KCNH2HTR2A | |
| Oxalic Acid SCHEMBL7396297 | 0.85 | HTR4 (0.74) | HTR4KCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL7394154 | 0.85 | HTR4 (0.66) | HTR4KCNH2HTR2A | |
| Oxalic Acid SCHEMBL8056984 | 0.85 | HTR4 (0.80) | HTR4KCNH2HTR2A | |
| SCHEMBL4923894 | 0.84 | HTR4 (0.63) | HTR4KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311295-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | Laboratoire Glaxosmithkline S.A.S. (FR) | 2003-05-21 | — | — | EP | claimed |
| WO-2002011766-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | LABORATOIRE GLAXOSMITHKLINE S.A.S. (FR) | 2002-02-14 | — | — | WO | claimed |
| US-20080125422-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | LABORATOIRE GLAXOSMITHKLINE S A S | 2008-05-29 | — | — | US | disclosed |
| US-20070015769-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | LABORATOIRE GLAXOSMITHKLINE S.A.S. | 2007-01-18 | — | — | US | disclosed |
| US-20050032866-A1 | The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | GLAXO GROUP LIMITED (GB) | 2005-02-10 | — | — | US | disclosed |
| EP-1311295-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | Laboratoire Glaxosmithkline S.A.S. (FR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002011766-A2 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL FIBRILLATION | LABORATOIRE GLAXOSMITHKLINE S.A.S. (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125422-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | HTR4, TPH1, HTR1A | HTR4 1/4885KCNH2 421/4885HTR2A 17/4885 |
| US-20050032866-A1 | The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | HTR4, HTR1A, TPH1 | HTR4 1/4885KCNH2 415/4885HTR2A 16/4885 |
| US-20070015769-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | HTR4, HTR1A, TPH1 | HTR4 1/4885KCNH2 414/4885HTR2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.